Scarica l'app Stockscreener
3.89
1.27%
-0.05
Pre-mercato:
3.86
-0.03
-0.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.94
Aprire:
$3.95
Volume 24 ore:
3.56M
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.20B
Reddito:
$360.78M
Utile/perdita netta:
$-23.91M
Rapporto P/E:
-49.81
EPS:
-0.0781
Flusso di cassa netto:
$13.07M
1 W Prestazione:
-2.75%
1M Prestazione:
+15.09%
6M Prestazione:
-35.06%
1 anno Prestazione:
+3.18%
Intervallo 1D:
$3.88
$4.06
Intervallo di 1 settimana:
$3.83
$4.06
Portata 52W:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.89 | 1.22B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MannKind Corp (MNKD) Institutional Confidence - TradingKey
MannKind Corp (MNKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Insider Monkey
MANNKIND CORP (MNKD) Stock Chart - ChartMill
7 Hidden Penny Stocks to Invest In - Insider Monkey
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
MannKind (MNKD) Stock Price, News & Analysis - MarketBeat
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Jim Cramer Says He Blessed MannKind as a Speculation Only - Insider Monkey
MannKind highlights wider role for Afrezza at ADA 2026 - The Pharma Letter
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends - Sahm
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply - Insider Monkey
MannKind shares more data backing inhaled insulin - Drug Delivery Business
New data affirm safety and efficacy of MannKind's Afrezza inhaled insulin for children and adults with diabetes. - Pluang
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions - Quiver Quantitative
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Insider Monkey
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news - AD HOC NEWS
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Assessing MannKind (MNKD) Valuation After Recent Share Price Momentum And Royalty Growth Expectations - simplywall.st
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - Yahoo Finance
MannKind stock surges on United Therapeutics partnership deal - Investing.com
5 Most Promising Penny Stocks According to Wall Street Analysts - Insider Monkey
MannKind (MNKD) Announces Milestones in Nintedanib DPI Development for IPF - GuruFocus
MannKind (MNKD) Announces Milestones in Nintedanib DPI Developme - GuruFocus
MannKind completes patient enrollment in nintedanib DPI trials - Investing.com
MannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026 - Quiver Quantitative
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD) - Seeking Alpha
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial ReliefHas The Bull Case Changed? - Yahoo Finance
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Barchart.com
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
US FDA approves MannKind's inhaled insulin for children - Reuters
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):